Analysis of clinically relevant variants from ancestrally diverse Asian genomes.
Sock Hoai ChanYasmin BylstraJing Xian TeoJyn Ling KuanNicolas BertinMar Gonzalez-PortaMaxime HebrardRoberto Tirado-MagallanesJoanna Hui Juan TanJustin JeyakaniZhihui LiJin Fang ChaiYap Seng ChongSonia DavilaLiuh Ling GohEng Sing LeeEleanor WongTien Yin Wongnull nullShyam PrabhakarJian-Jun LiuChing-Yu ChengBirgit EisenhaberNeerja KarnaniKhai Pang LeongXueling S SimKhung Keong YeoJohn C ChambersE-Shyong TaiPatrick Boon-Ooi TanSaumya Shekhar JamuarJoanne Ngeow Yuen YieWeng Khong LimPublished in: Nature communications (2022)
Asian populations are under-represented in human genomics research. Here, we characterize clinically significant genetic variation in 9051 genomes representing East Asian, South Asian, and severely under-represented Austronesian-speaking Southeast Asian ancestries. We observe disparate genetic risk burden attributable to ancestry-specific recurrent variants and identify individuals with variants specific to ancestries discordant to their self-reported ethnicity, mostly due to cryptic admixture. About 27% of severe recessive disorder genes with appreciable carrier frequencies in Asians are missed by carrier screening panels, and we estimate 0.5% Asian couples at-risk of having an affected child. Prevalence of medically-actionable variant carriers is 3.4% and a further 1.6% harbour variants with potential for pathogenic classification upon additional clinical/experimental evidence. We profile 23 pharmacogenes with high-confidence gene-drug associations and find 22.4% of Asians at-risk of Centers for Disease Control and Prevention Tier 1 genetic conditions concurrently harbour pharmacogenetic variants with actionable phenotypes, highlighting the benefits of pre-emptive pharmacogenomics. Our findings illuminate the diversity in genetic disease epidemiology and opportunities for precision medicine for a large, diverse Asian population.
Keyphrases